

FOI – 2268

28th March 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

[a] Data on numbers of patients from the electronic prescribing system

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	
1.2 Dupilumab (Dupixent)	
1.3 Mepolizumab (Nucala)	
1.4 Omalizumab (Xolair)	
1.5 Reslizumab (Cinqaero)	
1.6 Tezepelumab (Tezspire)	

Response:

Not held as no electronic prescribing system in use within the Trust

Q2. How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Severe asthma (please include all types or	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other

	references to asthma)			
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				
2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

Response:

Not held as no electronic prescribing system in use within the Trust

Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)			
3.2 Dupilumab (Dupixent)			
3.3 Mepolizumab (Nucala)			
3.4 Omalizumab (Xolair)			
3.5 Reslizumab (Cinqaero)			
3.6 Tezepelumab (Tezspire)			

Response:

Not held as no electronic prescribing system in use within the Trust

[b] data on usage of medicines from the hospital pharmacy system

Fields to include in the data extract from the hospital pharmacy database:

Field	
Calendar year	
Calendar month	
Name of Health Board / Trust	
Drug substance (INN name of drug)	
Drug product pack name	Virtual or actual product pack name
Quantity unit of measure (UOM)	e.g. tablet, mL, vial, the unit in which the quantity can be measured
Quantity issued	

Filters

- Time period: Jan 2019 to Feb 2024, or the latest available month
- Drugs to include:
 - Benralizumab (Fasenra) – *not stocked*
 - Dupilumab (Dupixent)

Sum of quantity		Inkfy	2018/19	2019/20	2021/22	2022/23	2023/24	Grand Total	
Drugnam/INN	Strength	Inkmon							
DUPIXENT	200 mg in 1.14ml	October					1	1	
	200 mg in 1.14ml Total						1	1	
	300 mg in 2mL	January		9		2	3		14
		February		14					14
		March		14			1		15
		April			17			1	18
		May			2			1	3
		June			4		2	2	8
		July			0		1	6	7
		August			5		2	3	10
		September						0	1
		October						1	1
		November						6	6
		December							2
300 mg in 2mL Total			37	28	2	16	17	100	
DUPIXENT Total			37	28	2	16	18	101	
Grand Total			37	28	2	16	18	101	

- Mepolizumab (Nucala) 1ml pre-filled syringe

Sum of quantity		Inkfy					
c_drugname	Inkmon	19/20	20/21	21/22	23/24	Grand Total	
MEPOLIZUMAB (NUCALA)	January	2	1	1	1	5	
	February	1				1	
	March	2	1			3	
	April		1			1	
	May		2			2	
	June		1			1	
	July		1		1	2	
	August		1			1	
	September		1			1	
	October	1	2			3	
	November		1	2		3	
	December	1	3			4	
MEPOLIZUMAB (NUCALA) Total		7	15	3	2	27	
Grand Total		7	15	3	2	27	

○ **Omalizumab (Xolair)**

Sum of Quantity		Year							
Drugname/INN	Month	18/19	19/20	20/21	21/22	22/23	23/24	(blank)	Grand Total
OMALIZUMAB (XOLAIR) 150mg in 1 ml	January	24	26		66	32	51		199
	February	28	24	36	50	80	72		290
	March	17	54	54	54	60			239
	April		18	40	42	54	60		214
	May		13		36	36	82		167
	June		18	22	42	62	58		202
	July		20	30	48	58	52		208
	August		28	28	34	64	90		244
	September		18	24	30	58	70		200
	October		28	30	108	52	56		274
	November		22	18	54	54	90		238
	December		38	58	22	96	92		306
OMALIZUMAB (XOLAIR) 150mg in 1 ml Total		69	307	340	586	706	773		2781
(blank)	(blank)								
(blank) Total									
Grand Total		69	307	340	586	706	773		2781

- **Reslizumab (Cinqaero)** - *not stocked*
- **Tezepelumab (Tezspire)** - *not stocked*

Email: foi.team@southerntrust.hscni.net